Pharmaceutical industry wants special pricing for new antibioticsGerman pharmaceutical lobby vfa called for special pricing procedures for new antibiotics that are efficient against multi-resistant bacteria, FAZ reports on Friday (p26) (APMHE 64344).
Bayer streamlines management boardBayer's management board will be reduced from seven to five members and, in return, heads of of the three divisions will have more responsibilities, Handelsblatt (p26) and Die Welt (p9) reported on Wednesday (APMHE 64310).
Analysts see Evotec shares risingAnalysts from all eight banks following German biotech Evotec recommend buying shares, Handelsblatt report on Friday (p34).
Gates Foundation partners with BioNTechThe Bill & Melinda Gates Foundation has signed a partnership over $55 million with Germany's BioNTech to develop vaccine and immunotherapy candidates in HIV and tuberculosis, FAZ reported on Saturday (p57) (APMHE 64247).
Warning on biotin vitaminsBiotin-based vitamins, sold as dietary supplements to strengthen hair, skin and fingernails, can induce false blood results, weekly Der Spiegel said on Saturday (p107)
Purdue deal over opioid crisis not to end litigationThe present deal, under which Purdue and the family would pay $12 billion in total to over 2,000 U.S. states, municipalities and hospitals, would not end litigation, as 16 states have not accepted the offer, according to TV reports, Süddeutsche Zeitung (SZ) (p26) and FAZ (p26) report on Friday (APMHE 64331).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.